The ADMIRE Network organized a themed issue of the British Journal of Pharmacology entitled
Edited by: Achim Lother, Ulrich Wenzel, Frédéric Jaisser
Br J Pharmacol. 2022;179(13):3235-3249.
2024
Mohib MM, Rabe S, Nolze A, Rooney M, Ain Q, Zipprich A, Gekle M, Schreier B. Eplerenone, a mineralocorticoid receptor inhibitor, reduces cirrhosis associated changes of hepatocyte glucose and lipid metabolism. Cell Commun Signal. 2024;22(1):614. doi: 10.1186/s12964-024-01991-2
Deng L, Pollmeier L, Bednarz R, Cao C, Laurette P, Wirth L, Mamazhakypov A, Bode C, Hein L, Gilsbach R, Lother A. Atlas of cardiac endothelial cell enhancer elements linking the mineralocorticoid receptor to pathological gene expression. Sci Adv. 2024;10(10):eadj5101. doi: 10.1126/sciadv.adj5101
Fraccarollo D, Geffers R, Galuppo P, Bauersachs J. Mineralocorticoid receptor promotes cardiac macrophage inflammaging. Basic Res Cardiol. 2024. doi: 10.1007/s00395-024-01032-6
2023
Koca D, Lother A. Molecular pharmacology of mineralocorticoid receptor antagonists: The role of co-regulators. Steroids. 2023;199:109291.
Zhu Z, Rosenkranz KA, Kusunoki Y, Li C, Klaus M, Gross O, Angelotti ML, Antonelli G, Cirillo L, Romagnani P, Bouteldja N, Sadr AV, Bülow RD, Boor P, Anders HJ. Finerenone Added to RAS/SGLT2 Blockade for Chronic Kidney Disease in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice. J Am Soc Nephrol. 2023;34(9):1513-1520
Gallego A, Pérez P. Loss of epidermal glucocorticoid receptor protects against whole body metabolic dysfunction upon chronic corticosterone treatment. Mol Metab. 2023;74:101763.
Kintscher U, Edelmann F. The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction. Cardiovasc Diabetol. 2023;22(1):162.
Carceller-Zazo E, Sevilla LM, Pons-Alonso O, Chiner-Oms Á, Amazit L, An Vu T, Vitellius G, Viengchareun S, Comas I, Jaszczyszyn Y, Abella M, Alegre-Martí A, Estébanez-Perpiñá E, Lombès M, Pérez P. The mineralocorticoid receptor modulates timing and location of genomic binding by glucocorticoid receptor in response to synthetic glucocorticoids in keratinocytes. FASEB J. 2023;37(1):e22709
Mamazhakypov A, Lother A. Therapeutic targeting of mineralocorticoid receptors in pulmonary hypertension: Insights from basic research. Front Cardiovasc Med. 2023;10:1118516.
2022
Luettges K, Bode M, Diemer JN, Schwanbeck J, Wirth EK, Klopfleisch R, Kappert K, Thiele A, Ritter D, Foryst-Ludwig A, Kolkhof P, Wenzel UO, Kintscher U. Finerenone Reduces Renal RORγt γδ T Cells and Protects against Cardiorenal Damage. Am J Nephrol. 2022;53(7):552-564.
Bauersachs J, Lother A. Mineralocorticoid receptor activation and antagonism in cardiovascular disease: cellular and molecular mechanisms. Kidney Int Suppl (2011). 2022;12(1):19-26.